- Home
- PTGX vs TBBK Comparison
PTGX vs TBBK Comparison
Compare PTGX & TBBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTGX
- TBBK
- Stock Information
- Founded
- PTGX 2006
- TBBK 1999
- Country
- PTGX United States
- TBBK United States
- Employees
- PTGX N/A
- TBBK N/A
- Industry
- PTGX Biotechnology: Pharmaceutical Preparations
- TBBK Major Banks
- Sector
- PTGX Health Care
- TBBK Finance
- Exchange
- PTGX Nasdaq
- TBBK Nasdaq
- Market Cap
- PTGX 2.8B
- TBBK 2.7B
- IPO Year
- PTGX 2016
- TBBK 2004
- Fundamental
- Price
- PTGX $47.91
- TBBK $50.51
- Analyst Decision
- PTGX Strong Buy
- TBBK Buy
- Analyst Count
- PTGX 7
- TBBK 3
- Target Price
- PTGX $52.83
- TBBK $55.00
- AVG Volume (30 Days)
- PTGX 450.1K
- TBBK 564.7K
- Earning Date
- PTGX 11-08-2024
- TBBK 10-24-2024
- Dividend Yield
- PTGX N/A
- TBBK N/A
- EPS Growth
- PTGX N/A
- TBBK 16.52
- EPS
- PTGX 2.75
- TBBK 3.95
- Revenue
- PTGX $319,120,000.00
- TBBK $472,015,000.00
- Revenue This Year
- PTGX $400.33
- TBBK N/A
- Revenue Next Year
- PTGX N/A
- TBBK $7.05
- P/E Ratio
- PTGX $17.54
- TBBK $12.71
- Revenue Growth
- PTGX 125.73
- TBBK 6.71
- 52 Week Low
- PTGX $13.76
- TBBK $29.92
- 52 Week High
- PTGX $48.89
- TBBK $59.26
- Technical
- Relative Strength Index (RSI)
- PTGX 60.40
- TBBK 44.27
- Support Level
- PTGX $45.33
- TBBK $45.82
- Resistance Level
- PTGX $48.89
- TBBK $59.26
- Average True Range (ATR)
- PTGX 1.28
- TBBK 2.17
- MACD
- PTGX 0.11
- TBBK -0.96
- Stochastic Oscillator
- PTGX 77.11
- TBBK 35.86
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
About TBBK The Bancorp Inc
The Bancorp Inc is a financial holding company, through its subsidiary it is engaged in specialty lending namely securities-backed lines of credit, vehicle fleet and another equipment leasing, Small Business Administration lending, insurance policy cash value-backed lines of credit and commercial mortgage-backed loans, generated for sale into commercial mortgage-backed securities markets through securitizations. The company deposits and non-interest income are generated in the payments business which consists of issuing, acquiring, and automated clearing house accounts.